Table 2.

Selected adverse events in patients with metastatic urothelial carcinoma

All patients with metastatic urothelial carcinoma (n = 19)
	Grades 1–2	Grade 3	Grade 4	Grade 5
Non-haematological
Diarrhoea	8 (42%)	1 (5%)	0	0
Nausea	3 (16%)	0	0	0
Anorexia	4 (21%)	0	0	0
Fatigue	5 (26%)	2 (11%)	0	0
Oral mucositis	3 (16%)	1 (5%)	0	0
Pancreatitis	0	1 (5%)	0	0
Dysgeusia	3 (16%)	0	0	0
Hypertension	2 (11%)	0	0	0
Rash (acneiform)	4 (21%)	0	0	0
Rash (maculopapular)	0	1 (5%)	0	0
Pneumonitis	3 (16%)	0	0	0
Intracranial haemorrhage	0	0	0	1 (5%)
Pneumothorax	0	1 (5%)	0	0
Pruritis	0	1 (5%)	0	0
Weight loss	4 (21%)	0	0	0
Elevated AST	2 (11%)	2 (11%)	0	0
Elevated ALT	4 (21%)	0	0	0
Hypercholesterolaemia	2 (11%)	0	0	0
Viral hepatitis	0	1 (5%)	0	0
Hyperglycaemia	5 (26%)	0	0	0
Hypertriglyceridemia	4 (21%)	0	0	0
Hyperuricemia	0	0	1 (5%)	0
Hypomagnesemia	4 (21%)	0	0	0
Hypophosphatemia	6 (31%)	4 (21%)	0	0
Elevated lipase	1 (5%)	1 (5%)	0	0
Hyponatremia	1 (5%)	1 (5%)	0	0
Haematological
Anaemia	2 (11%)	0	0	0
Neutropenia	0	1 (5%)	0	0
Leukopenia	2 (11%)	0	0	0
Lymphopenia	0	0	1 (5%)	0
Thrombocytopenia	5 (26%)	2 (11%)	0	0

Selected grades 1–2 (in at least 10% of patients) and grades 3, 4, and 5 adverse events

AST aspartate aminotransferase, ALT alanine aminotransferase